ABIOMED, Inc. (ABMD) Shares Bought by Victory Capital Management Inc.

Victory Capital Management Inc. boosted its position in ABIOMED, Inc. (NASDAQ:ABMD) by 21.7% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 9,761 shares of the medical equipment provider’s stock after acquiring an additional 1,738 shares during the quarter. Victory Capital Management Inc.’s holdings in ABIOMED were worth $1,399,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Virginia Retirement Systems ET AL increased its stake in ABIOMED by 350.0% in the second quarter. Virginia Retirement Systems ET AL now owns 7,200 shares of the medical equipment provider’s stock valued at $1,032,000 after acquiring an additional 5,600 shares during the last quarter. State Board of Administration of Florida Retirement System increased its stake in ABIOMED by 2.1% in the second quarter. State Board of Administration of Florida Retirement System now owns 56,307 shares of the medical equipment provider’s stock valued at $8,069,000 after acquiring an additional 1,176 shares during the last quarter. Redwood Investments LLC increased its stake in ABIOMED by 10.2% in the second quarter. Redwood Investments LLC now owns 60,628 shares of the medical equipment provider’s stock valued at $8,688,000 after acquiring an additional 5,603 shares during the last quarter. BB&T Securities LLC increased its stake in ABIOMED by 1.0% in the second quarter. BB&T Securities LLC now owns 4,154 shares of the medical equipment provider’s stock valued at $595,000 after acquiring an additional 43 shares during the last quarter. Finally, Turner Investments LLC increased its stake in ABIOMED by 4.3% in the second quarter. Turner Investments LLC now owns 9,600 shares of the medical equipment provider’s stock valued at $1,376,000 after acquiring an additional 400 shares during the last quarter. 89.84% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: “ABIOMED, Inc. (ABMD) Shares Bought by Victory Capital Management Inc.” was first posted by Stock Observer and is the sole property of of Stock Observer. If you are reading this report on another website, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this report can be viewed at https://www.thestockobserver.com/2017/09/13/abiomed-inc-abmd-shares-bought-by-victory-capital-management-inc.html.

A number of research analysts recently commented on ABMD shares. Morgan Stanley reissued an “equal weight” rating and issued a $140.00 target price (up previously from $135.00) on shares of ABIOMED in a research note on Monday, July 10th. Zacks Investment Research cut ABIOMED from a “buy” rating to a “hold” rating in a research note on Wednesday, July 5th. BidaskClub cut ABIOMED from a “buy” rating to a “hold” rating in a research note on Saturday, August 26th. Jefferies Group LLC raised their price objective on ABIOMED from $165.00 to $175.00 and gave the company a “buy” rating in a research note on Friday, August 4th. Finally, Piper Jaffray Companies reaffirmed an “overweight” rating and set a $160.00 price objective (up from $145.00) on shares of ABIOMED in a research note on Thursday, July 27th. Three analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $158.29.

Shares of ABIOMED, Inc. (NASDAQ ABMD) opened at 157.91 on Wednesday. ABIOMED, Inc. has a 1-year low of $95.14 and a 1-year high of $158.28. The company has a market capitalization of $6.93 billion, a PE ratio of 92.35 and a beta of 0.22. The company has a 50 day moving average price of $150.78 and a 200 day moving average price of $137.10.

ABIOMED (NASDAQ:ABMD) last issued its quarterly earnings results on Thursday, July 27th. The medical equipment provider reported $0.45 EPS for the quarter, beating the consensus estimate of $0.42 by $0.03. The company had revenue of $132.47 million for the quarter, compared to the consensus estimate of $130.83 million. ABIOMED had a net margin of 16.13% and a return on equity of 13.03%. The firm’s revenue was up 28.6% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.29 EPS. Equities analysts predict that ABIOMED, Inc. will post $2.24 EPS for the current fiscal year.

In related news, Director Eric A. Md Rose sold 982 shares of the company’s stock in a transaction dated Wednesday, August 30th. The shares were sold at an average price of $145.17, for a total transaction of $142,556.94. Following the transaction, the director now directly owns 13,634 shares in the company, valued at approximately $1,979,247.78. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO David M. Weber sold 16,500 shares of the company’s stock in a transaction dated Monday, July 31st. The shares were sold at an average price of $147.63, for a total transaction of $2,435,895.00. Following the transaction, the chief operating officer now owns 125,122 shares in the company, valued at $18,471,760.86. The disclosure for this sale can be found here. Insiders have sold a total of 50,500 shares of company stock worth $7,603,342 over the last quarter. 7.00% of the stock is currently owned by insiders.

About ABIOMED

ABIOMED, Inc is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart.

Want to see what other hedge funds are holding ABMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ABIOMED, Inc. (NASDAQ:ABMD).

Institutional Ownership by Quarter for ABIOMED (NASDAQ:ABMD)

Receive News & Ratings for ABIOMED Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply